Emadodin Tohidi, Mehran Ghaemi, Mohammad Sadegh Golvajouei
{"title":"A review on camelid nanobodies with potential application in veterinary medicine.","authors":"Emadodin Tohidi, Mehran Ghaemi, Mohammad Sadegh Golvajouei","doi":"10.1007/s11259-024-10432-x","DOIUrl":null,"url":null,"abstract":"<p><p>The single variable domains of camelid heavy-chain only antibodies, known as nanobodies, have taken a long journey since their discovery in 1989 until the first nanobody-based drug's entrance to the market in 2022. On account of their unique properties, nanobodies have been successfully used for diagnosis and therapy against various diseases or conditions. Although research on the application of recombinant antibodies has focused on human medicine, the development of nanobodies has paved the way for incorporating recombinant antibody production in favour of veterinary medicine. Currently, despite many efforts in developing these biomolecules with diversified applications, significant opportunities exist for exploiting these highly versatile and cost-effective antibodies in veterinary medicine. The present study attempts to identify existing gaps and shed light on paths for future research by presenting an updated review on camelid nanobodies with potential applications in veterinary medicine.</p>","PeriodicalId":23690,"journal":{"name":"Veterinary Research Communications","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Research Communications","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1007/s11259-024-10432-x","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
The single variable domains of camelid heavy-chain only antibodies, known as nanobodies, have taken a long journey since their discovery in 1989 until the first nanobody-based drug's entrance to the market in 2022. On account of their unique properties, nanobodies have been successfully used for diagnosis and therapy against various diseases or conditions. Although research on the application of recombinant antibodies has focused on human medicine, the development of nanobodies has paved the way for incorporating recombinant antibody production in favour of veterinary medicine. Currently, despite many efforts in developing these biomolecules with diversified applications, significant opportunities exist for exploiting these highly versatile and cost-effective antibodies in veterinary medicine. The present study attempts to identify existing gaps and shed light on paths for future research by presenting an updated review on camelid nanobodies with potential applications in veterinary medicine.
期刊介绍：
Veterinary Research Communications publishes fully refereed research articles and topical reviews on all aspects of the veterinary sciences. Interdisciplinary articles are particularly encouraged, as are well argued reviews, even if they are somewhat controversial.
The journal is an appropriate medium in which to publish new methods, newly described diseases and new pathological findings, as these are applied to animals. The material should be of international rather than local interest. As it deliberately seeks a wide coverage, Veterinary Research Communications provides its readers with a means of keeping abreast of current developments in the entire field of veterinary science.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
